Should I Get Screened for Prostate Cancer? A Look at the Evidence

Hands Hold Show Light Blue Ribbon Prostate Cancer Awareness

By Dr. Wesley Ludwig, M.D.

Prostate-specific antigen (PSA) is an enzyme secreted by the prostate gland. PSA produced in small amounts in the blood of men with healthy prostates is normal, but PSA is elevated in the presence of prostate cancer.

PSA screening for prostate cancer was done routinely for years but has become a heavily debated subject. Currently, the United States Preventive Services Task Force (USPSTF), a volunteer panel of experts in general disease prevention, has given PSA screening a Grade C for men ages 55 to 69. This means there is moderate certainty in a small net benefit to screening and physicians should selectively offer PSA screening to patients based on professional judgment and patient preference.

The American Urological Association (AUA), an organization of experts in the field of urological diseases, recommends that men ages 55 to 69 undergo shared decision making with their physician and that the greatest benefit to screening is in this age group. As the decision to undergo screening strongly involves patient preference, an understanding of the evidence supporting PSA screening is crucial.

A Brief History of PSA

PSA was first discovered in the 1970’s and was approved in the 1980’s by the FDA to monitor prostate cancer recurrence. In 1991, Catalona et al. published a seminal paper in the New England Journal of Medicine showing that PSA was a good predictor of a prostate cancer diagnosis.[1] PSA soon became a widely used screening test throughout the United States for asymptomatic men.

Following this, the incidence of prostate cancer skyrocketed. The figure below from SEER data displays this rapid increase. Prior to routine PSA testing, 1 in 10 men were diagnosed with prostate cancer. After widespread PSA testing, 1 in 6 men were diagnosed with prostate cancer. Corresponding to this, in the mid 90’s mortality due to prostate cancer began to decline at a rate of approximately 4% per year, as seen in the graph below. This may have been due to an increase in PSA screening, however, some have suggested it is due to earlier and increasingly aggressive prostate cancer treatments beginning around the same time period.

Prostate cancer incidence and mortality before, during and after the introduction of PSA testing, 1975-2011.

PSA and evidence from the screening trials

Eventually, several randomized control trials were performed to determine if screening for prostate cancer using PSA conferred a prostate cancer survival benefit. Perhaps the two best designed studies were the Prostate, Lung, Colorectal and Ovarian Screening Trial (PLCO) and the European Randomized Study of Screening for Prostate Cancer (ERSPC) which are summarized below. [2,3]

Number of patients 76,693 162,243
Age range 55-74 55-69
PSA interval Annually for 6 years Every 2 to 4 years
Median follow-up ~13 years ~13 years
Contamination ~77% ~20%
Prostate cancer

specific mortality

Risk Reduction

(screen v control)



In summary, PLCO is an American trial that enrolled men aged 55-74 to a screening or non-screening arm. After 10 years of follow-up there was no improvement in prostate cancer specific mortality in the screened group. However, this study has been criticized for its high level of contamination. This refers to the fact that a large percentage of men in the non-screening arm (approximately 77%) had a PSA level tested during the study.

PLCO did not compare screening to non-screening; it compared routine screening to opportunistic screening, which is very prevalent in the US.

The ERSPC is a European trial of men aged 55 to 69 randomized to a screened arm that received PSA screening every 2 to 4 years and a non-screening group. The contamination rate was much lower in the ERSPC trial as routine PSA tests are uncommon throughout Europe. The 13-year update of this study shows that a man’s risk of dying of prostate cancer is 21% less when screened for prostate cancer. 781 men would need to be screened and 27 cancers would need to be diagnosed to save one life from prostate cancer.[3] Additionally, subsets of the ERSPC study have been followed for 19 years and have shown an even greater reduction in metastatic disease and cancer-specific mortality in patients that underwent screening [4].

However, there are important negative associations with PSA screening that have been noted in the scientific literature and are summarized in the table below.

Harm Estimate Source
False positive 75.9% Proportion w PSA >3, negative bx (ERSPC)
Overdiagnosis 66%
Screen detected, 4 year interval (ERSPC)
Modelling studies (Heijnsdijk et al 2009) [5]
Post-biopsy fever 4% Loeb et al 2012 ERSPC [6]
Post-biopsy hospitalization 1% Loeb et al 2012 ERSPC [6]
Hematuria/hematospermia 20-50% Post-biopsy (ERSPC)
Incontinence/ED 20-30% All treatment types (Chou et al 2011, USPSTF meta-analysis) [7]
Death 1-5/1000 Within 1 month of surgery (Chou et al 2011, USPSTF meta-analysis) [7]

In Summary

  • Professional medical societies recommend discussing PSA screening with your physician and making a shared decision regarding screening.
  • A well-performed clinical trial comparing PSA screening and non-screening found a reduction in metastatic disease and death due to prostate cancer for men that underwent PSA screening.
  • There are several harms associated with PSA screening including overtreatment and complications associated with biopsy and surgery.
  • Patients should weigh the risks and benefits of PSA screening according to their values and preferences and discuss these with their physicians.


  1. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA, Andriole GL. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991 Apr 25;324(17):1156-61. Erratum in: N Engl J Med 1991 Oct 31;325(18):1324.
  2. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, Fouad MN, Isaacs C, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O’Brien B, Ragard LR, Clapp JD, Rathmell JM, Riley TL, Hsing AW, Izmirlian G, Pinsky PF, Kramer BS, Miller AB, Gohagan JK, Prorok PC; PLCO Project Team. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012 Jan 18;104(2):125-32. doi: 10.1093/jnci/djr500. Epub 2012 Jan 6.
  3. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, Kwiatkowski M, Lujan M, Määttänen L, Lilja H, Denis LJ, Recker F, Paez A, Bangma CH, Carlsson S, Puliti D, Villers A, Rebillard X, Hakama M, Stenman UH, Kujala P, Taari K, Aus G, Huber A, van der Kwast TH, van Schaik RH, de Koning HJ, Moss SM, Auvinen A; for the ERSPC Investigators. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014 Aug 6. pii: S0140-6736(14)60525-0. doi: 10.1016/S0140-6736(14)60525-0. [Epub ahead of print]
  4. Osses DFRemmers SSchröder FHvan der Kwast TRoobol MJ. Results of Prostate Cancer Screening in a Unique Cohort at 19yr of Follow-up. Eur Urol. 2019 Mar;75(3):374-377. doi: 10.1016/j.eururo.2018.10.053. Epub 2018 Nov 9.
  5. Heijnsdijk EA, der Kinderen A, Wever EM, Draisma G, Roobol MJ, de Koning HJ. Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer. Br J Cancer. 2009 Dec 1;101(11):1833-8. doi: 10.1038/sj.bjc.6605422. Epub 2009 Nov 10.
  6. Loeb S, van den Heuvel S, Zhu X, Bangma CH, Schröder FH, Roobol MJ. Infectious complications and hospital admissions after prostate biopsy in a European randomized trial. Eur Urol. 2012 Jun;61(6):1110-4. doi: 10.1016/j.eururo.2011.12.058. Epub 2012 Jan 5.
  7. Chou R, Dana T, Bougatsos C, Fu R, Blazina I, Gleitsmann K, Rugge JB. Treatments for Localized Prostate Cancer: Systematic Review to Update the 2002 U.S. Preventive Services Task Force Recommendation [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2011

Patient Overcomes Prostate Cancer, Credits Dr. Sharpe

Urologist meets with patient overcomes prostate cancer

After surviving a trio of brain surgeries to remove a tumor, Victor Bedzyk, a retired electrical engineer, would face yet another health challenge: prostate cancer.

In late 2016, Bedzyk received the news from Dr. Brent Sharpe. With Bedzyk’s prostate-specific antigen (PSA) numbers on the rise, Dr. Sharpe suggested a prostate biopsy. The test came back positive for cancer.

Although Dr. Sharpe believed the cancer was contained to the prostate, he found evidence of the disease on the borders of the organ. The physician suggested several options, including prostate removal.

“I researched all of the options,” Bedzyk said, “but a prostatectomy made the most sense to me. There’s no point of doing something that might come back on you like a boomerang.”

Using the da Vinci Surgical System, an advanced form of robotic surgical equipment, Dr. Sharpe performed the minimally-invasive procedure from a console with joystick-like controls. The machine translated the surgeon’s movements into smaller, precise movements of tiny instruments inside Bedzyk’s body.

According to Dr. Sharpe, this was the first time a patient was discharged the same day following a prostatectomy in Georgia. Today, Dr. Sharpe said Georgia Urology is the only practice in the state offering a same-day discharge prostatectomy.

Although he faced a challenging recuperation period, Bedzyk remained confident he chose wisely. And Dr. Sharpe soon provided confirmation. Once the prostate was removed, a full biopsy revealed more cancer than was previously discovered.

“Even though you have to go through recovery and side effects, you have your life ahead of you,” said Bedzyk, who credits his resilience to a strong faith, a supportive family, and a positive attitude.

Dr. Sharpe’s skill and professional aptitude bolstered Bedzyk’s confidence in his physician and resulted in an ongoing doctor-patient relationship.

“He’s brilliant,” said Bedzyk. “Dr. Sharpe’s brain comprehends so much, so quickly. He gets to the core issues and sees what needs to be done. … He tries to stay on the frontline of his field and aware of all the things he can do. …I’m grateful for that.”

Today Bedzyk said he savors life, from spending time with his wife and grandchildren to building a boat in his home workshop. Cancer remains undetectable, and Bedzyk continues having his PSA checked regularly. He encourages other men to be diligent, too.

“You can’t get tested too early,” Bedzyk said. “At age 52, my brother found out he had stage IV prostate cancer. And a lot of people don’t start checking until they’re in their 60s or late 50s. …Prostate cancer is a danger, for sure. So I always recommend men keep a urologist among their roster of physicians.”

If you are facing a prostate cancer diagnosis, click here to get in touch with our expert urology team.

MRI Guided Fusion Prostate Biopsy: A New Tool Against Prostate Cancer

By Dr. Jerry Yuan, M.D.

Many advances have been made in the last decade in the diagnosis and treatment of prostate cancer. A great example is a prostate MRI guided biopsy or the fusion Bx. It represents a quantum leap forward when indicated. This allows for more accurate identification of those with elevated PSAs necessitating prostate biopsies, as well as more precise biopsies to better assess the extent of disease to guide further therapy.

While standard ultrasound (TRUS) based biopsy continues to be appropriate in many men, some require a different approach. This includes men in whom cancer is suspected despite a prior normal biopsy, as well as men with rather enlarged prostates which render detection quite difficult.

At Georgia Urology, with assistance from Northside Hospital and its outstanding Radiology Dept, we utilize the Eigen Artemis ProFuse Bx.

Who Would Receive an MRI Guided Fusion Prostate Biopsy?

We’ve provided an example of such a case! Here are the qualities of our index patient:

  • A man with a PSA of 5.6 who underwent a negative TRUS/12 core Bx in 2016.
  • His PSA is now 6.5 & a secondary biomarker test (SelectMDx in this case) returned at moderate risk for cancer detection.

In this instance, the MRI confirmed the presence of a 1 cm suspicious lesion on the left side of the gland. Here are the photos:

MRI Guided Fusion Prostate Biopsy live US image
Live US image matching the MRI derived prostate boundary (green outline) with target lesion in red and the predicted path & sample length of the biopsy needle to ensure proper sampling.
US image captured, outlined & refine of MRI Guided Fusion Prostate Biopsy
US image captured, outlined and refined to create a US derived facsimile of the MRI.
Two MRI Guided Fusion Prostate Biopsy images
MRI (right) and US (left) are now matched in multiple planes to superimpose live US images onto the MRI.
MRI Guided Fusion Prostate Biopsy computer rendering
Fusion complete with a computer rendering of the prostate highlighting the target lesion(s).
MRI Guided Fusion Prostate Biopsy MRI mapped preop with lesion highlighted in red
MRI mapped preop with lesion highlighted in red.

How Does an MRI Guided Fusion Prostate Biopsy Work?

The procedure is well tolerated. It’s performed under a light general anesthesia since movement will degrade the accuracy of targeting.

As in the majority of cases performed, the cancer detection rate is quite high, ranging from 50% to near 100% depending on the grade of the lesion based on the MRI criteria. Our index patient was found to have Gleason 4 prostate cancer in the index lesion and 2 adjacent locations thanks to the MRI Guided Fusion Prostate Biopsy.

Contact the expert urologists at Georgia Urology to learn more about this form of diagnosis and treatment for prostate cancer, plus more.

Georgia Urology Patient Faces Prostate Cancer With Positivity

patient success story Jack standing by his wife before prostate cancer

“You probably have prostate cancer.”

When Jack Francisco heard those words from his primary care physician, they rattled his already challenging world. It was late summer 2010, and Jack’s wife, Lee, was in the midst of recuperating from her second breast cancer surgery. A financial planner by trade, Jack recognized he and his wife’s own future plans lay in the balance.

Jack’s prostate-specific antigen (PSA) test had resulted in a remarkably high number, 59. All signs were pointing toward prostate cancer. Reading online articles about the disease, Jack fell down a rabbit hole of negative information, and he feared the worst.  

He soon found solace in Dr. Lewis Kriteman of Georgia Urology. After an initial examination, additional testing, and a biopsy, Dr. Kriteman found evidence of prostate cancer. The physician offered treatment options, and recommended a combination of hormone and radiation therapy.

“Dr. Kriteman also gave me some excellent guidance on what the side effects of the treatment would be and the length of time it would take,” Jack said. “And he gave me dietary and exercise recommendations to make sure and maximize the treatment efficacy and minimize the side effects.”

A definitive plan of action helped stabilize Jack’s anxiety, and he and Dr. Kriteman began moving forward.

In the meantime, Lee was receiving chemotherapy and radiation. Inspired by his wife’s strength and positivity, Jack trudged forward with newfound optimism. The extensive nature of her treatment required Jack to tend to his wife’s needs.

“She needed a lot more support than I did,” he said. “I think that helped me a great deal. I wasn’t dwelling on what I was going through.”

The couple went through radiation together. Lee had her treatment in the mornings, and Jack’s took place in the evenings. Throughout this experience, they sought perspective and the healing power of humor.

“We used to joke that we didn’t need to turn the lights on at night, because we were both glowing from the radiation,” Jack said.

In addition to the strength found within his marriage, Jack relished the “tremendous level of care” and tactical approach he received from Dr. Kriteman.

After approximately 90 days of treatment, Jack’s PSA plummeted to an undetectable level. Remaining diligent, Dr. Kriteman kept his patient on hormone therapy for the next three years.

Throughout this journey, Jack used his own experience and perspective to support others facing a prostate cancer diagnosis. From comforting colleagues to forging friendships on an online prostate cancer support forum, Jack chose to pay it forward.

Now age 68, Jack continues seeing Dr. Kriteman for quarterly tests and exams, and the disease is undetectable.

Jack and Lee are currently enjoying retirement. This includes golfing, traveling, cooking, woodworking, and spending time with their grandchildren. Relying on mantras such as “look for the good,” “get living” and “everyday is a gift,” help pave a road of positivity.

“My wife told me we have to look at it as diseases we’re going to manage,” Jack explained. “We have no guarantee we’re ever going to be cured. If we’re cured, that’s great. If we’re not, it’s not the end of the world. Much of this can be well managed, but we have to stay on top of it. And that’s the approach we’re taking.”

Prostate Cancer Rehabilitation

happy patient and doctor discuss prostate cancer rehabilitation treatments.

By Dr. Brent A. Sharpe, M.D.

1:9 men in the US will have prostate cancer. While that in itself can be frightening enough, many men also fear prostate cancer treatments. This fear mainly stems from the potential complications of erectile dysfunction, or ED, and urinary incontinence that may occur with curative therapy. The two most common types of these therapies for localized prostate cancer are surgery and radiation.

However, with advancements in technology and the utilization of experienced radiation oncologists and high volume surgeons, these complications can be minimized through prostate cancer rehabilitation procedures.

Here is how the experts at Georgia Urology look to do just that.

Use a Combination of Treatments for Prostate Cancer Rehabilitation

First, there are several measures that prostate cancer specialists normally take to reduce the recovery time for ED and incontinence. Most high volume surgeons will use a combination of oral and penile medications, as well as vacuum erection devices to help recover the erectile function sooner. For the urinary incontinence, they usually enlist a specialized physical therapist who concentrates on pelvic floor training in order to help patients recover quickly.

Persistent incontinence and ED rates are approximately 5% and 30-40% after these treatments, respectively. However, there is still hope for these men!

Urological Prostheses

Medical prosthesis are devices which can be surgically implanted into patients and are great options for prostate cancer rehabilitation. Common examples are joint replacements and pacemakers. With the advent of urological prosthesis, essentially all permanent ED and incontinent patients have excellent curative options available to restore normal function. These options have been shown to have patient and partner satisfaction rates of 96% and 90%, respectively.  

A prosthetic urologist is a urologist with specialized training and interest in urological prostheses. They can help patients select the best device for their specific set of circumstances. Here are just a few of the options.

  • Penile implants are devices that can be implanted into patients with significant ED and they are able to restore normal sexual function. To date, more than 500,000 penile implants have been placed. This surgery is an outpatient procedure that is normally done in less than one hour and most patients return to normal activity in 1-2 weeks. There are three types of devices and most result in a normal flaccid and erect penile state.
  • Male urinary slings are a piece of material which is surgically placed underneath the urethra to allow repositioning and mild compression to restore urinary continence. The success rates for male sling exceeds 90%.
  • If patients are experiencing more severe incontinence, then an artificial urinary sphincter, AUS, maybe a better choice. An AUS is a device that takes the place of the native sphincter which was damaged by prostate cancer treatment. This is a balloon that wraps around the urethra to maintain continence and is deactivated by the patient in order to empty their bladder. The placement of an AUS, with its 98% patient satisfaction rate, is one of the most patient satisfying procedures in all of medicine.

As a prosthetic urologist, one of my personal stories is of a patient who was wearing 12 diapers per day. After having an AUS placed, he was able to resume his normal life. Both male slings and artificial urinary sphincters can be used to restore complete continence in men who have undergone prostate cancer treatment and can be done as an outpatient surgery.

As one can see, men should not have to fear treatment for prostate cancer. Prostate cancer cure rates are excellent, >90%, and side effects are minimal and treatable with complete restoration of normal function.

It is the role of the prosthetic urologist to restore every man who underwent prostate cancer treatment with full sexual function and continence. One could say their motto is, “Live long, happy and dry!”

Here at Georgia Urology, we have countless expert urologists here to help you remain confident after your treatments for with prostate cancer rehabilitation. Contact us if you want to learn more or schedule an appointment with any of our team members.

Cryosurgery: A Treatment for Prostate Cancer

happy patient after Cryosurgery.

By Dr. Barry M. Zisholtz, M.D., F.A.C.S.

Many patients and physicians are aware of the more common treatments for prostate cancer, such as surgical removal of the gland and radiation therapy with or without seed implantation. However, some people have not heard of cryosurgery, a procedure that freezes a growth and destroys the tumor by delivering cold ice to temperatures of minus 40 degrees Celsius (-40 degrees Fahrenheit).

Benefits and Risks of Cryosurgery

Cryosurgery is a minimally invasive procedure. Many times, it’s preferred to more traditional kinds of surgery because of its minimal pain and scarring.

However, as with any medical treatment, there are risks involved, primarily that of damage to nearby healthy tissue. Damage to nerve tissue is of particular concern. In addition, patients undergoing cryosurgery usually experience redness and minor local pain or discomfort.

Who Should Get Cryosurgery?

While this treatment has been used to treat prostate cancer for over 20 years, it’s a newer technology that has become very safe and effective and almost always performed as an outpatient procedure. Here are the patients this particular surgery will benefit the most:

  • It is an excellent choice for men who have a recurrence after radiation and in selective individuals.
  • It is a great primary treatment, especially for an elderly man with a small about of disease.
  • In selective patients, cryosurgery of the prostate can be focused on a selective area of the gland without freezing the entire prostate. That is important in men who wish to preserve their potency.

How Does Cryosurgery Work?

The procedure is performed in the operation room without any incisions.

Depending upon the size of the prostate, small needles called 6-8 Cryo probes are directed into the prostate using ultrasound guidance. Two freezing cycles are performed and a catheter is left at the end of the procedure for a few days to allow any swelling to resolve.

Post-operative instructions involve ice packs and catheter care, as there is usually not much pain.

Patients are monitored over the months and years with physical exams and PSA blood tests similar to after surgery or radiation therapy.

This is a procedure that can be repeated if needed, especially in a patient who initially had a focal treatment.

If you’re interested to hear more about cryosurgery, contact the expert at Georgia Urology today!

What Advances Have Been Made in the Diagnosis and Treatment of Prostate Cancer?

By Dr. Barry Zisholtz, M.D., F.A.C.S

Featured in Atlanta Magazine

What medical advances have been made with Prostate Cancer

Prostate cancer is the most common solid organ cancer in men. Last year there were 164,690 new cases, and 29,430 deaths related to prostate cancer. While the incidence varies in different countries, genetic makeup, diet, and exposure to carcinogens contribute to the development of the disease. White males over fifty have a higher likelihood of developing the disease, and black males more frequently develop a more aggressive type of prostate cancer.

The good news is that there are new advances in the diagnosis and treatment of prostate cancer.

There are a significant number of men with an elevated prostate-specific antigen blood test who undergo expensive and invasive testing looking for prostate cancer. Many of them don’t have the disease. Recently there have been breakthrough developments of new genetic markers and more efficient diagnostic testing that can help determine whether or not a biopsy is needed. These tests may involve the collection of blood and urine and even an MRI of the gland.

There are a wide variety of treatment options available for prostate cancer patients depending upon the aggressiveness and stage of the disease. These include, removing the prostate with a minimally invasive incision or a robotic procedure; radiation with or without seed implantation, cryosurgery (an outpatient technique that freezes the prostate gland); and HIFU (high-intensity focused ultrasound, which destroys the cancerous tissue with ultrasound waves). In some cases with a very slow growing tumor, the patient may elect to do active surveillance where he is monitored at regular intervals.

If you want to learn more about the advances in the diagnosis and treatment of prostate cancer, contact the experts at Georgia Urology. 

Georgia Urology co-sponsors Community Conversation on Prostate Cancer presented by Bayer

Dr. Darrell Carmen joined event’s physician panel to boost disease awareness, proactivity

Georgia Urology continued its local outreach by participating in another program to help boost prostate cancer awareness and proactivity among African-American men. This free-to-the-public event, entitled Bayer Presents Community Conversation on Prostate Cancer, took place 10 a.m. February 17 at Omega Psi Phi Fraternity (3951 Snapfinger Parkway, Decatur).

The event included complimentary prostate cancer screenings and lunch. In addition to Georgia Urology and Bayer, other sponsors of the event included the Georgia Prostate Cancer Coalition, Radiotherapy Clinics of Georgia, Prostate Conditions Education Council, and Clark Atlanta University.

Georgia Urology’s Dr. Darrell Carmen addressed the importance of Prostate-Specific Antigen (PSA) testing and keeping a keen eye on one’s test results. Other panelists discussed topics ranging from prostate cancer treatment options and prostate cancer research in African-Americans. According to the Prostate Cancer Foundation, African Americans are 1.6 times more likely to develop prostate cancer than Caucasians, and 2.4 times more likely to die from the disease.

“Prostate cancer has truly become an epidemic in the African-American community,” Dr. Carmen said. “It all begins with open, honest discussions that promote awareness and education.”

Attendees were able to take that awareness and put it into action on the spot. Georgia Urology hosted free prostate cancer screenings at the event. A volunteer staff from Georgia Urology was on hand to conduct the screenings. Georgia Urology physicians always recommend that when men reach age 40, they consider a prostate cancer screening with a PSA test. Statistics reveal that one in six men will be affected by prostate cancer in their lifetime.

One member of the volunteer staff, Medical Assistant Chantal Jordan, formed a special connection during the event. She was able to meet with several of the men who mentor her son in Omega Psi Phi’s Project Uplift program.

“The program has been amazing for my son for the past year, so it was an honor to connect with those who have done so much for him,” Chantal explained.

“The men of Omega Psi Phi attempt to answer the call to fill many needs,” said Andrew Porter, chair of the Project Uplift program. “We have been honored to know Chantal’s son and support him to make a positive difference in his life. We’ve also been honored to help promote health in this community through hosting this event.”

Other special guests included 11Alive meteorologist Chesley McNeil, who will serve as host. A roster of former NFL players were on hand for a special meet-and-greet with audience members.

Dr. Darrell Carmen practices out of the Camp Creek (3890 Redwine Road, Suite 112, Atlanta. 404-766-7151) and Riverdale (33 Upper Riverdale Road S.W., Suite 105, Riverdale. 770-991-0020) Georgia Urology locations. Dr. Carmen is a member of the American Urological Association, National Medical Association, American Association of Clinical Urologists, and American College of Surgeons. With specialized training in robotic surgery and InterStim therapy, Dr. Carmen has urologic expertise in prostate cancer, erectile dysfunction, penile implant surgery, urinary incontinence, and kidney stones.

Check out the photos from the event below!

Dr. Darrell Carmen appears on “Your Health Connection” radio show on Jazz 91.9 WCLK

September 21, 2017 — As a part of National Prostate Health Month, Dr. Darrell Carmen appeared on the season premiere of “Your Health Connection” on Jazz 91.9 WCLK to discuss the pervasive disease. The hour-long show was hosted by The Center for Cancer Research and Therapeutic Development (CCRTD) and Paula Gwynn Grant and featured Dr. Shafiq Khan and Mr. Rudy Morgan. Dr. Khan is professor and Director of the CCRTD at Clark Atlanta University, and Mr. Morgan is a prostate cancer survivor.

During the show, Dr. Carmen shared his vast expertise in preventing, diagnosing, and treating prostate cancer. He also took calls from listeners who had questions about the disease.

If you didn’t get a chance to listen live, click the link to hear Dr. Carmen on WCLK’s “Your Health Connection” show!